JABET
SearchSign In/UpSubmit Manuscript
Home
Special IssuesEditorial BoardAnnouncements
RSS Feed
Original article| Open access | J Adv Biotechnol Exp Ther. 2025; 8(2): 259-271|doi: 10.5455/jabet.2025.22

Development of gelatin particles encapsulating PDGF-BB aptamer for the efficient drug delivery system

Abstract

Drug delivery systems (DDSs) improve therapy through controlled release and targeted delivery, utilizing recognition elements, therapeutic agents, and carriers. Among various recognition elements, aptamers have gained attention for their high affinity and specificity. Gelatin, a biocompatible and biodegradable material, shows potential for DDSs due to its favorable properties. This study investigated gelatin-based particles for aptamer delivery, focusing on their preparation, characterization, and evaluation. Gelatin particles loaded with platelet-derived growth factor-BB (PDGF-BB) aptamer were prepared using glutaraldehyde as a crosslinker, with sodium dodecyl sulfonate (SDS) and Tween 20 as stabilizers. The particles were characterized through spectroscopy techniques, dynamic light scattering (DLS), and scanning electron microscopy (SEM). The reaction between aldehyde and amine groups was confirmed, and the effect of surfactants on particle formation was examined. Aptamer release and stability were also studied. The ninhydrin assay and Fourier-transform infrared (FTIR) analysis confirmed successful crosslinking between gelatin and glutaraldehyde, forming stable particles. Zeta potential measurements showed that both SGP and TGP maintained stability within the range of -30 to -60 mV. Particle size analysis via DLS and SEM revealed that increasing surfactant concentration led to larger particles, with sizes ranging from 95 to 120 nm. Weight loss studies demonstrated that SGP followed zero-order kinetics while TGP exhibited first-order degradation, with both retaining over 90% of their weight within 72 hours. Aptamer release studies showed that SGP had a higher release rate than TGP, correlating with their degradation profiles. Finally, electrophoresis confirmed the integrity of released aptamers, emphasizing the protective role of gelatin particles. Overall, gelatin-based particles show promise for aptamer delivery, offering stability and controlled release. These findings contribute to the advancement of effective DDSs for targeted therapeutic delivery.

Keywords

References

  • [1]Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13:813-27.
  • [2]Rotkrua P, Lohlamoh W, et al. A molecular hybrid comprising as1411 and pdgf-bb aptamer, cholesterol, and doxorubicin for inhibiting proliferation of sw480 cells. J Mol Recognit. 2021;34.
  • [3]Tan HS, Hou N, et al. Cd133 antibody targeted delivery of gold nanostars loading 18820 and docetaxel for multimodal imaging and near-infrared photodynamic/photothermal/chemotherapy against castration resistant prostate cancer. Nanomed-Nanotechnol Biol Med. 2020;27:11.
  • [4]Mourtas S, Lazar AN, et al. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for alzheimer disease. Eur J Med Chem. 2014;80:175-83.
  • [5]Ruan HT, Yao SY, et al. Stapled rap12 peptide ligand of lrp1 for micelles-based multifunctional glioma-targeted drug delivery. Chem Eng J. 2021;403:12.
  • [6]Chen ML, Amerigos J, et al. Folate receptor-targeting and reactive oxygen species-responsive liposomal formulation of methotrexate for treatment of rheumatoid arthritis. Pharmaceutics. 2019;11:23.
  • [7]Fletcher NL, Houston ZH, et al. Designed multifunctional polymeric nanomedicines: Long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials. Chem Commun. 2018;54:5.
  • [8]Yan XF, Yang Y, et al. Gambogic acid grafted low molecular weight heparin micelles for targeted treatment in a hepatocellular carcinoma model with an enhanced anti-angiogenesis effect. Int J Pharm. 2017;522:110-8.
  • [9]Huang SS, Wei SC, et al. Gold nanoparticles modified with self-assembled hybrid monolayer of triblock aptamers as a photoreversible anticoagulant. J Control Release. 2016;221:9-17.
  • [10]Tseng YC, Mozumdar S, et al. Lipid-based systemic delivery of sirna. Adv Drug Deliv Rev. 2009;61:721-31.
  • [11]Oh EJ, Park K, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release. 2010;141:2-12.
  • [12]Islam N, Dmour I, et al. Degradability of chitosan micro/nanoparticles for pulmonary drug delivery. Heliyon. 2019;5:9.
  • [13]Segers VFM, Lee RT. Local delivery of proteins and the use of self-assembling peptides. Drug Discov Today. 2007;12:561-8.
  • [14]Sun N, Liu M, et al. Chitosan nanofibers for specific capture and nondestructive release of ctcs assisted by pcbma brushes. Small. 2016;12:5090-7.
  • [15]Hao XJ, Silva EA, et al. Angiogenic effects of sequential release of vegf-a(165) and pdgf-bb with alginate hydrogels after myocardial infarction. Cardiovascular Research. 2007;75:178-85.
  • [16]Venkatesh S, Wower J, et al. Nucleic acid therapeutic carriers with on-demand triggered release. Bioconjugate Chem. 2009;20:1773-82.
  • [17]Ma YK, Ge YX, et al. Advancement of multifunctional hybrid nanogel systems: Construction and application in drug co-delivery and imaging technique. Mater Sci Eng C-Mater Biol Appl. 2017;71:1281-92.
  • [18]Tungkavet T, Sirivat A, et al. Stress relaxation behavior of (ala-gly-pro-arg-gly-glu-4hyp-gly-pro-) gelatin hydrogels under electric field: Time-electric field superposition. Polymer. 2013;54:2414-21.
  • [19]Hudson D, Margaritis A. Biopolymer nanoparticle production for controlled release of biopharmaceuticals. Critical Reviews in Biotechnology. 2014;34:161-79.
  • [20]Tungkavet T, Seetapan N, et al. Improvements of electromechanical properties of gelatin hydrogels by blending with nanowire polypyrrole: Effects of electric field and temperature. Polymer International. 2012;61:825-33.
  • [21]Ozeki M, Ishii T, et al. Controlled release of hepatocyte growth factor from gelatin hydrogels based on hydrogel degradation. Journal of Drug Targeting. 2001;9:461-71.
  • [22]Fukunaka Y, Iwanaga K, et al. Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. Journal of Controlled Release. 2002;80:333-43.
  • [23]Sun SG. Technology evaluation: Selex, gilead sciences inc. Current Opinion in Molecular Therapeutics. 2000;2:100-5.
  • [24]Proske D, Blank M, et al. Aptamers--basic research, drug development, and clinical applications. Appl Microbiol Biotechnol. 2005;69:367-74.
  • [25]Soontornworajit B, Wang Y. Nucleic acid aptamers for clinical diagnosis: Cell detection and molecular imaging. Anal Bioanal Chem. 2011;399:1591-9.
  • [26]Zhan Y, Ma W, et al. DNA-based nanomedicine with targeting and enhancement of therapeutic efficacy of breast cancer cells. ACS Applied Materials and Interfaces. 2019;11:15354-65.
  • [27]Yazdian-Robati R, Bayat P, et al. Therapeutic applications of as1411 aptamer, an update review. Int J Biol Macromol. 2020;155:1420-31.
  • [28]Soliman AG, Mahmoud B, et al. Optimized synthesis characterization and protective activity of quercetin and quercetin–chitosan nanoformula against cardiotoxicity that was induced in male wister rats via anticancer agent: Doxorubicin. Cancer Nanotechnology. 2023;14.
  • [29]Soontornworajit B, Zhou J, et al. Aptamer-functionalized in situ injectable hydrogel for controlled protein release. Biomacromolecules. 2010;11:2724-30.
  • [30]Bahoor A, Ahmadi R, et al. Synthesis and evaluation of cross-linked gelatin nanoparticles for controlled release of an anti-diabetic drug: Gliclazide. Inorganic Chemistry Communications. 2023;154.
  • [31]Dilruba Öznur KG, Ayşe Pınar TD. Statistical evaluation of biocompatibility and biodegradability of chitosan/gelatin hydrogels for wound-dressing applications. Polymer Bulletin. 2024;81:1563-96.
  • [32]Zhang W, Shen H, et al. Preparation of type-a gelatin/poly-γ-glutamic acid nanoparticles for enhancing the stability and bioavailability of (-)-epigallocatechin gallate. Foods. 2023;12.
  • [33]Santoro M, Tatara AM, et al. Gelatin carriers for drug and cell delivery in tissue engineering. J Control Release. 2014;190:210-8.
  • [34]Aljaber MB, Verisqa F, et al. Influence of gelatin source and bloom number on gelatin methacryloyl hydrogels mechanical and biological properties for muscle regeneration. Biomolecules. 2023;13.
  • [35]Soontornworajit B, Kerdsiri K, et al. Aptamer-gelatin composite material for prolonging pdgf-bb release. Songklanakarin Journal of Science and Technology. 2020;42:180-7.
  • [36]Vaziri A, Warburton B. Some preparative variables influencing the properties of w/o/w multiple emulsions. Journal of Microencapsulation. 1994;11:649-56.
  • [37]Özyildiz F, Karagönlü S, et al. Micro-encapsulation of ozonated red pepper seed oil with antimicrobial activity and application to nonwoven fabric. Letters in Applied Microbiology. 2013;56:168-79.
  • [38]Zhang T, Ding M, et al. Droplet and creaming stability of fish oil-loaded gelatin/surfactant-stabilized emulsions depends on both the adsorption ways of emulsifiers and the adjusted ph. Food Science and Human Wellness. 2020;9:280-8.
  • [39]Ma X, Wang T, et al. Formulation and physicochemical and biological characterization of etoposide-loaded submicron emulsions with biosurfactant of sophorolipids. AAPS PharmSciTech. 2022;23:181.
  • [40]Mishra V, Nayak P, et al. Orally administered self-emulsifying drug delivery system in disease management: Advancement and patents. Expert Opin Drug Deliv. 2021;18:315-32.
  • [41]Nitta SK, Numata K. Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. International Journal of Molecular Sciences. 2013;14:1629-54.
  • [42]Aljabali AAA, Rezigue M, et al. Protein-based nanomaterials: A new tool for targeted drug delivery. Therapeutic Delivery. 2022;13:321-38.
  • [43]Li K, Zhou D, et al. Size-transformable gelatin/nanochitosan/doxorubicin nanoparticles with sequentially triggered drug release for anticancer therapy. Colloids and Surfaces B: Biointerfaces. 2022;220.
  • [44]Lee J, Ban E, et al. Stability enhancement of freeze-dried gelatin/alginate coacervates for bfgf delivery. Pharmaceutics. 2022;14.
  • [45]Lei S, Gao Y, et al. Dual-rna controlled delivery system inhibited tumor growth by apoptosis induction and tme activation. J Control Release. 2022;344:97-112.
  • [46]Hamaguchi N, Ellington A, et al. Aptamer beacons for the direct detection of proteins. Analytical Biochemistry. 2001;294:126-31.
  • [47]Stojanovic MN, Kolpashchikov DM. Modular aptameric sensors. J Am Chem Soc. 2004;126:9266-70.
  • [48]Keefe AD, Schaub RG. Aptamers as candidate therapeutics for cardiovascular indications. Current Opinion in Pharmacology. 2008;8:147-52.
  • [49]Keefe AD, Pai S, et al. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9:537-50.
  • [50]Sae-Lim S, Soontornworajit B, et al. Inhibition of colorectal cancer cell proliferation by regulating platelet-derived growth factor b signaling with a DNA aptamer. Asian Pac J Cancer Prev. 2019;20:487-94.

Article Info

Academic Editor

Hasan-Al-Faruque, PhD; University of Utah, USA
Received
03 December, 2024
Accepted
11 March, 2025
Published
17 March, 2025
Article DOI:10.5455/jabet.2025.22

Coresponding author

Boonchoy Soontornworajit Department of Chemistry, Faculty of Science and Technology, Thammasat University, Pathumthani ,Thailand. Email: sbooncho@tu.ac.th

Cite this article

Pikulthong W, Aunkitkancharoen P, et al. Development of gelatin particles encapsulating PDGF-BB aptamer for the efficient drug delivery system. J Adv Biotechnol Exp Ther. 2025; 8(2): 259-271.